Enterprise Value

184.2M

Cash

74.82M

Avg Qtr Burn

-7.722M

Short % of Float

6.81%

Insider Ownership

7.56%

Institutional Own.

15.17%

Qtr Updated

12/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Phase 2

Data readout

Onvansertib (monotherapy) Details
Cancer, Small cell lung cancer

Phase 2

Data readout

Phase 2

Data readout

Onvansertib + Zytiga (abiraterone) Details
Prostate cancer, Cancer, Castration-resistant prostate cancer

Phase 2

Update

Phase 2

Update

Onvansertib + Paclitaxel Details
Cancer, Triple-negative breast cancer

Phase 1/2

Update

Failed

Discontinued